The REgistry Study on Multimodality trEAtment foR Cerebral Hemorrhage (RESEARCH)

October 3, 2024 updated by: Tao Liu
The REgistry Study on multimodality trEAtment foR Cerebral Hemorrhage (RESEARCH) aims to address these challenges by establishing a comprehensive national registry. This initiative will collect detailed, longitudinal data on the clinical characteristics, treatment modalities, and outcomes of patients with ICH across various regions. By leveraging a wide array of treatment data - including medical management, surgical interventions, and rehabilitative strategies - the RESEARCH registry intends to provide a granular view of current treatment landscapes and their direct impact on patient recovery and quality of life.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Cerebral hemorrhage, also known as intracerebral hemorrhage (ICH), is a severe neurological condition characterized by abrupt bleeding within the brain tissues, leading to high rates of mortality and morbidity worldwide. In China, where the burden of cerebrovascular diseases is substantial due to the aging population and prevalence of risk factors such as hypertension and diabetes, the impact of ICH is particularly pronounced. Despite advancements in medical science, the prognosis for patients suffering from ICH remains poor, with a high proportion of survivors experiencing significant disability.

Current treatment protocols for ICH involve a range of strategies, from conservative management to surgical interventions. However, the heterogeneity in clinical practices and patient responses highlights a significant gap in standardized treatment efficacy.

This registry study is not only pivotal for enhancing the understanding of effective treatment combinations but also crucial for identifying potential disparities in the application of treatment modalities across different healthcare settings. Through the analytical power of this large-scale, multicentric data, RESEARCH will contribute significantly to optimizing treatment paradigms and ultimately, shaping policy changes that aim to reduce the mortality and enhance the recovery rates of patients suffering from cerebral hemorrhage.

There is an urgent need to evaluate these multimodal treatment approaches on a broader scale to understand their real-world effectiveness and develop guidelines that can be systematically applied to improve patient outcomes.

Study Type

Observational

Enrollment (Estimated)

100000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Cerebral hemorrhage from various causes

Description

Inclusion Criteria:

  • Cerebral hemorrhage

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
modified Rankin Score (mRS)
Time Frame: at least 6 months
0=no symptoms, 1=no significant disability, 2=slight disability, 3= moderate disability, 4=moderate severe disability, 5=severe disability, 6=death
at least 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tao Liu

Collaborators

Xuanwu Hospital, Beijing
Tianjin Medical University General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 15, 2024

Primary Completion (Estimated)

October 15, 2044

Study Completion (Estimated)

October 15, 2049

Study Registration Dates

First Submitted

October 3, 2024

First Submitted That Met QC Criteria

October 3, 2024

First Posted (Actual)

October 8, 2024

Study Record Updates

Last Update Posted (Actual)

October 8, 2024

Last Update Submitted That Met QC Criteria

October 3, 2024

Last Verified

October 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Thegeorgeinstitute
  • 82071390 (Other Grant/Funding Number: National Natural Science Foundation of China)
  • 82271394 (Other Grant/Funding Number: National Natural Science Foundation of China)
  • 8247050928 (Other Grant/Funding Number: National Natural Science Foundation of China)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intracerebral Hemorrhage

Clinical Trials on medical management, surgical interventions, and rehabilitative strategies

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe